Results 271 to 280 of about 542,975 (311)
Some of the next articles are maybe not open access.
Programmed death-1 pathway in cancer and autoimmunity
Clinical Immunology, 2014Programmed death-1 (PD-1) is a co-receptor that is expressed predominantly by T cells. The binding of PD-1 to its ligands, PD-L1 or PD-L2, is vital for the physiologic regulation of the immune system. A major functional role of the PD-1 signaling pathway is the inhibition of self-reactive T cells, which serve to protect against autoimmune diseases ...
Ariel, Pedoeem +4 more
openaire +2 more sources
Cloning and identification of porcine programmed death 1
Veterinary Immunology and Immunopathology, 2010Programmed death 1 (PD-1) is a member of the immunoglobulin (Ig) superfamily, which is expressed on activated T cells, B cells and monocytes. Many researches have demonstrated that a high level of PD-1 expression is closely related to persistent infection and immune evasion in some human infections.
Jin-Mei, Peng +9 more
openaire +2 more sources
European Journal of Cancer, 2013
Programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibodies have changed the landscape in oncology in 2013. The most mature results have been obtained in advanced melanoma patients. They indicate important response rates and high quality responses or prolonged duration.
Caroline, Robert +2 more
openaire +2 more sources
Programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibodies have changed the landscape in oncology in 2013. The most mature results have been obtained in advanced melanoma patients. They indicate important response rates and high quality responses or prolonged duration.
Caroline, Robert +2 more
openaire +2 more sources
Recent Patents on Anti-Cancer Drug Discovery, 2016
Inhibitors of immune check-point molecule, programmed cell death 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1) have attracted much attention in cancer immunotherapy recently due to their durable antitumor effects in various malignances, especially the advanced ones. Unfortunately, only a fraction of patients with advanced tumors could
Xiao-Na, Fang, Li-Wu, Fu
openaire +2 more sources
Inhibitors of immune check-point molecule, programmed cell death 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1) have attracted much attention in cancer immunotherapy recently due to their durable antitumor effects in various malignances, especially the advanced ones. Unfortunately, only a fraction of patients with advanced tumors could
Xiao-Na, Fang, Li-Wu, Fu
openaire +2 more sources
Targeting Programmed Cell Death 1 in Ovarian Cancer
Journal of Clinical Oncology, 2015Reference EPFL-ARTICLE-216550doi:10.1200/Jco.2015.63.7785View record in Web of Science Record created on 2016-02-16, modified on 2016-08 ...
Homicsko, Krisztian, Coukos, George
openaire +4 more sources
Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis
Inflammation, 2015Programmed death-1 (PD-1) is an inhibitory co-receptor that is highly expressed in T lymphocytes that has been shown to downregulate inflammatory responses in several inflammatory diseases including systemic lupus erythematosus and rheumatoid arthritis. Yet, the role of PD-1 in psoriatic arthritis (PsA) has not been studied.
Michael, Peled +5 more
openaire +2 more sources
Expression of programmed death 1 is correlated with progression of osteosarcoma
APMIS, 2014Accumulating bodies of evidence indicate that immune dysregulation plays a key role in the development of osteosarcoma (OS). Programmed death 1 (PD‐1) is a surface receptor expressed on activated and exhausted T cells, which mediate T‐cell inhibition upon binding with its ligand. Researches on PD‐1 and OS remain extremely limited. Here, we investigated
Wenjie, Zheng +3 more
openaire +2 more sources
Association between programmed death-1 pathway and major depression
The World Journal of Biological Psychiatry, 2023Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immune mediators on the PD-1 pathway. However, previous data regarding the association between MD and PD-1 pathway were still scarce; therefore, we ...
Kuan-Wei Huang, Tiao-Lai Huang
openaire +2 more sources
Programmed death‐1 expression in cutaneous B‐cell lymphoma
Journal of Cutaneous Pathology, 2013BackgroundNumbers of programmed death‐1 (PD‐1) positive T cells have prognostic significance in some types of nodal B‐cell lymphomas, but data on PD‐1 expression in cutaneous B‐cell lymphoma (CBCL) are few. In this study we determined the expression and distribution of PD‐1 on neoplastic B cells and reactive T cells in skin sections from primary CBCLs ...
Cetinozman, F. +3 more
openaire +3 more sources
Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
Current Opinion in Oncology, 2015The development of 'immune checkpoint inhibitors' or drugs targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has been a stunning success of cancer immunotherapy. This review provides a timely overview of the biology and function of the PD-1 pathway and discusses the rationale for therapeutic inhibition of this pathway in ...
Chan Yoon, Cheah +2 more
openaire +2 more sources